PYPD - PolyPid GAAP EPS of $0.28 beats by $0.56

2023-05-10 07:25:24 ET

• PolyPid press release ( NASDAQ: PYPD ): Q1 GAAP EPS of $0.28 beats by $0.56 .
• As of March 31, 2023, the Company had cash and cash equivalents and deposits in the amount of $13.4 million,
• Research and development (R&D) expenses for the three months ended March 31, 2023, were $3.8 million, compared to $8.7 million in the same three-month period of 2022. The decrease in R&D expenses resulted primarily from the completion of the SHIELD I Phase 3 clinical trial.
• General and administrative (G&A) expenses for the three months ended March 31, 2023, were $1.6 million, compared to $2.5 million for the same period of 2022.
• Marketing and business development expenses for the three months ended March 31, 2023, were $0.4 million, compared to $0.8 million for the same period of 2022.

For further details see: